FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP
pharmaphorum
JUNE 23, 2024
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it hopes could find a use in more than a dozen diseases.
Let's personalize your content